Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in mice

Journal of Immunology

Volumn 192, Issue 11, 2014, Pages 5012-5022

  Tong, Qing ^a,b   He, Shan ^b,c   Xie, Fang ^b   Mochizuki, Kazuhiro ^b   Liu, Yongnian ^b,c   Mochizuki, Izumi ^b   Meng, Lijun ^c,d   Sun, Hongxing ^d   Zheng, Yanyun ^d   Guo, Yajun ^a   Hexner, Elizabeth ^e   Zhang, Yi ^b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROTEASOME; STAT4 PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CD4+ T LYMPHOCYTE; CELL MATURATION; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; TH1 CELL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANEMIA, APLASTIC; ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, KNOCKOUT; POLYCOMB REPRESSIVE COMPLEX 2; PROTEOLYSIS; RESPONSE ELEMENTS; STAT4 TRANSCRIPTION FACTOR; T-BOX DOMAIN PROTEINS; TH1 CELLS; TRANSCRIPTION, GENETIC;

EID: 84901252163     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302943     Document Type: Article

References (64)

1. Scheinberg, P., and N. S. Young. 2012. How I treat acquired aplastic anemia. Blood 120: 1185-1196.
2. Young, N. S., P. Scheinberg, and R. T. Calado. 2008. Aplastic anemia. Curr. Opin. Hematol. 15: 162-168.
3. Zeng, W., J. P. Maciejewski, G. Chen, and N. S. Young. 2001. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J. Clin. Invest. 108: 765-773.
4. Roderick, J. E., G. Gonzalez-Perez, C. A. Kuksin, A. Dongre, E. R. Roberts, J. Srinivasan, C. Andrzejewski, Jr., A. H. Fauq, T. E. Golde, L. Miele, and L. M. Minter. 2013. Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J. Exp. Med. 210: 1311-1329.
5. Sloand, E., S. Kim, J. P. Maciejewski, J. Tisdale, D. Follmann, and N. S. Young. 2002. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 100: 1185-1191.
6. Tang, Y., M. J. Desierto, J. Chen, and N. S. Young. 2010. The role of the Th1 transcription factor T-bet in a mouse model of immune-mediated bone-marrow failure. Blood 115: 541-548.
7. Young, N. S. 2000. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin. Hematol. 37: 3-14.
8. Young, N. S., and J. Maciejewski. 1997. The pathophysiology of acquired aplastic anemia. N. Engl. J. Med. 336: 1365-1372.
9. Young, N. S., A. Bacigalupo, and J. C. Marsh. 2010. Aplastic anemia: pathophysiology and treatment. Biol. Blood Marrow Transplant. 16(1, Suppl)S119-S125.
10. Blazar, B. R., W. J. Murphy, and M. Abedi. 2012. Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 12: 443-458.
11. Ferrara, J. L., J. E. Levine, P. Reddy, and E. Holler. 2009. Graft-versus-host disease. Lancet 373: 1550-1561.
12. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669.
13. Wilson, C. B., E. Rowell, and M. Sekimata. 2009. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 9: 91-105.
14. Zhou, L., M. M. Chong, and D. R. Littman. 2009. Plasticity of CD4+ T cell lineage differentiation. Immunity 30: 646-655.
15. Zhu, J., H. Yamane, and W. E. Paul. 2010. Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 28: 445-489.
16. Miller, S. A., and A. S. Weinmann. 2010. Molecular mechanisms by which T-bet regulates T-helper cell commitment. Immunol. Rev. 238: 233-246.
17. Solomou, E. E., K. Keyvanfar, and N. S. Young. 2006. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood 107: 3983-3991.
18. Dunker, A. K., and V. N. Uversky. 2010. Drugs for 'protein clouds': targeting intrinsically disordered transcription factors. Curr. Opin. Pharmacol. 10: 782-788.
19. Margueron, R., and D. Reinberg. 2011. The Polycomb complex PRC2 and its mark in life. Nature 469: 343-349.
20. Bantignies, F., and G. Cavalli. 2006. Cellular memory and dynamic regulation of polycomb group proteins. Curr. Opin. Cell Biol. 18: 275-283.
21. Schuettengruber, B., D. Chourrout, M. Vervoort, B. Leblanc, and G. Cavalli. 2007. Genome regulation by polycomb and trithorax proteins. Cell 128: 735-745.
22. He, S., Q. Tong, D. K. Bishop, and Y. Zhang. 2013. Histone methyltransferase and histone methylation in inflammatory T-cell responses. Immunotherapy 5: 989-1004.
23. Hod-Dvorai, R., E. Jacob, Y. Boyko, and O. Avni. 2011. The binding activity of Mel-18 at the Il17a promoter is regulated by the integrated signals of the TCR and polarizing cytokines. Eur. J. Immunol. 41: 2424-2435.
24. Jacob, E., R. Hod-Dvorai, O. L. Ben-Mordechai, Y. Boyko, and O. Avni. 2011. Dual function of polycomb group proteins in differentiated murine T helper (CD4+) cells. J. Mol. Signal. 6: 5.
25. Koyanagi, M., A. Baguet, J. Martens, R. Margueron, T. Jenuwein, and M. Bix. 2005. EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene silencing in Th1 cells. J. Biol. Chem. 280: 31470-31477.
26. Araki, Y., Z. Wang, C. Zang, W. H. Wood, III, D. Schones, K. Cui, T. Y. Roh, B. Lhotsky, R. P. Wersto, W. Peng, et al. 2009. Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells. Immunity 30: 912-925.
27. Wei, G., L. Wei, J. Zhu, C. Zang, J. Hu-Li, Z. Yao, K. Cui, Y. Kanno, T. Y. Roh, W. T. Watford, et al. 2009. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 30: 155-167.
28. He, S., F. Xie, Y. Liu, Q. Tong, K. Mochizuki, P. E. Lapinski, R. S. Mani, P. Reddy, I. Mochizuki, A. M. Chinnaiyan, et al. 2013. The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease. Blood 122: 4119-4128.
29. Chen, J., K. Lipovsky, F. M. Ellison, R. T. Calado, and N. S. Young. 2004. Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood 104: 1671-1678.
30. Chen, J., J. S. Brandt, F. M. Ellison, R. T. Calado, and N. S. Young. 2005. Defective stromal cell function in a mouse model of infusion-induced bone marrow failure. Exp. Hematol. 33: 901-908.
31. Chen, J., F. M. Ellison, M. A. Eckhaus, A. L. Smith, K. Keyvanfar, R. T. Calado, and N. S. Young. 2007. Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J. Immunol. 178: 4159-4168.
32. Su, I. H., A. Basavaraj, A. N. Krutchinsky, O. Hobert, A. Ullrich, B. T. Chait, and A. Tarakhovsky. 2003. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4: 124-131.
33. Zhang, Y., J. P. Louboutin, J. Zhu, A. J. Rivera, and S. G. Emerson. 2002. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J. Clin. Invest. 109: 1335-1344.
34. Fang, T. C., Y. Yashiro-Ohtani, C. Del Bianco, D. M. Knoblock, S. C. Blacklow, and W. S. Pear. 2007. Notch directly regulates Gata3 expression during T helper 2 cell differentiation. Immunity 27: 100-110.
35. Usui, T., R. Nishikomori, A. Kitani, and W. Strober. 2003. GATA-3 suppresses Th1 development by downregulation of Stat4 and not through effects on IL-12Rbeta2 chain or T-bet. Immunity 18: 415-428.
36. Zhu, J., B. Min, J. Hu-Li, C. J. Watson, A. Grinberg, Q. Wang, N. Killeen, J. F. Urban, Jr., L. Guo, andW. E. Paul. 2004. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat. Immunol. 5: 1157-1165.
37. Pearce, E. L., A. C. Mullen, G. A. Martins, C. M. Krawczyk, A. S. Hutchins, V. P. Zediak, M. Banica, C. B. DiCioccio, D. A. Gross, C. A. Mao, et al. 2003. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302: 1041-1043.
38. Pear, W. S., J. P. Miller, L. Xu, J. C. Pui, B. Soffer, R. C. Quackenbush, A. M. Pendergast, R. Bronson, J. C. Aster, M. L. Scott, and D. Baltimore. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92: 3780-3792.
39. Zhu, J., D. M. Giannola, Y. Zhang, A. J. Rivera, and S. G. Emerson. 2003. NF-Y cooperates with USF1/2 to induce the hematopoietic expression of HOXB4. Blood 102: 2420-2427.
40. Su, I. H., M. W. Dobenecker, E. Dickinson, M. Oser, A. Basavaraj, R. Marqueron, A. Viale, D. Reinberg, C. Wulfing, and A. Tarakhovsky. 2005. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121: 425-436.
41. Burbach, B. J., R. B. Medeiros, K. L. Mueller, and Y. Shimizu. 2007. T-cell receptor signaling to integrins. Immunol. Rev. 218: 65-81.
42. Ouyang, W., S. H. Ranganath, K. Weindel, D. Bhattacharya, T. L. Murphy, W. C. Sha, and K. M. Murphy. 1998. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 9: 745-755.
43. Berger, S. L. 2007. The complex language of chromatin regulation during transcription. Nature 447: 407-412.
44. Imamura, T., T. Haruta, Y. Takata, I. Usui, M. Iwata, H. Ishihara, M. Ishiki, O. Ishibashi, E. Ueno, T. Sasaoka, and M. Kobayashi. 1998. Involvement of heat shock protein 90 in the degradation of mutant insulin receptors by the proteasome. J. Biol. Chem. 273: 11183-11188.
45. Morinobu, A., M. Gadina, W. Strober, R. Visconti, A. Fornace, C. Montagna, G. M. Feldman, R. Nishikomori, and J. J. O'Shea. 2002. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc. Natl. Acad. Sci. USA 99: 12281-12286.
46. Chang, S., and T. M. Aune. 2007. Dynamic changes in histone-methylation 'marks' across the locus encoding interferon-gamma during the differentiation of T helper type 2 cells. Nat. Immunol. 8: 723-731.
47. Wei, J., O. Duramad, O. A. Perng, S. L. Reiner, Y. J. Liu, and F. X. Qin. 2007. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 104: 18169-18174.
48. Boyle, A. P., S. Davis, H. P. Shulha, P. Meltzer, E. H. Margulies, Z. Weng, T. S. Furey, and G. E. Crawford. 2008. High-resolution mapping and characterization of open chromatin across the genome. Cell 132: 311-322.
49. Roh, T. Y., S. Cuddapah, K. Cui, and K. Zhao. 2006. The genomic landscape of histone modifications in human T cells. Proc. Natl. Acad. Sci. USA 103: 15782-15787.
50. Jacob, E., R. Hod-Dvorai, S. Schif-Zuck, and O. Avni. 2008. Unconventional association of the polycomb group proteins with cytokine genes in differentiated T helper cells. J. Biol. Chem. 283: 13471-13481.
51. Xu, K., Z. J. Wu, A. C. Groner, H. H. He, C. Cai, R. T. Lis, X. Wu, E. C. Stack, M. Loda, T. Liu, et al. 2012. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338: 1465-1469.
52. Lewis, M. D., S. A. Miller, M. M. Miazgowicz, K. M. Beima, and A. S.Weinmann. 2007. T-bet's ability to regulate individual target genes requires the conserved T-box domain to recruit histone methyltransferase activity and a separate family member-specific transactivation domain. Mol. Cell. Biol. 27: 8510-8521.
53. Miller, S. A., A. C. Huang, M. M. Miazgowicz, M. M. Brassil, and A. S. Weinmann. 2008. Coordinated but physically separable interaction with H3K27-demethylase and H3K4-methyltransferase activities are required for T-box protein-mediated activation of developmental gene expression. Genes Dev. 22: 2980-2993.
54. Miller, S. A., S. E. Mohn, and A. S. Weinmann. 2010. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression. Mol. Cell 40: 594-605.
55. Kim, E., M. Kim, D. H. Woo, Y. Shin, J. Shin, N. Chang, Y. T. Oh, H. Kim, J. Rheey, I. Nakano, et al. 2013. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23: 839-852.
56. Morin, R. D., N. A. Johnson, T. M. Severson, A. J. Mungall, J. An, R. Goya, J. E. Paul, M. Boyle, B. W. Woolcock, F. Kuchenbauer, et al. 2010. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42: 181-185.
57. Varambally, S., S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda, D. Ghosh, K. J. Pienta, R. G. Sewalt, A. P. Otte, et al. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
58. He, S., J. Wang, K. Kato, F. Xie, S. Varambally, S. Mineishi, R. Kuick, K. Mochizuki, Y. Liu, E. Nieves, et al. 2012. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood 119: 1274-1282.
59. Kato, K., S. Cui, R. Kuick, S. Mineishi, E. Hexner, J. L. Ferrara, S. G. Emerson, and Y. Zhang. 2010. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease. Biol. Blood Marrow Transplant. 16: 751- 771.
60. Knutson, S. K., T. J. Wigle, N. M. Warholic, C. J. Sneeringer, C. J. Allain, C. R. Klaus, J. D. Sacks, A. Raimondi, C. R. Majer, J. Song, et al. 2012. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8: 890-896.
61. Konze, K. D., A. Ma, F. Li, D. Barsyte-Lovejoy, T. Parton, C. J. Macnevin, F. Liu, C. Gao, X. P. Huang, E. Kuznetsova, et al. 2013. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8: 1324-1334.
62. McCabe, M. T., H. M. Ott, G. Ganji, S. Korenchuk, C. Thompson, G. S. Van Aller, Y. Liu, A. P. Graves, A. Della Pietra, III, E. Diaz, et al. 2012. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-112.
63. Qi, W., H. Chan, L. Teng, L. Li, S. Chuai, R. Zhang, J. Zeng, M. Li, H. Fan, Y. Lin, et al. 2012. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. USA 109: 21360-21365.
64. Wang, A., D. Pan, Y. H. Lee, G. J. Martinez, X. H. Feng, and C. Dong. 2013. Cutting edge: Smad2 and Smad4 regulate TGF-b-mediated Il9 gene expression via EZH2 displacement. J. Immunol. 191: 4908-4912.